Key result
TG2 knockdown reduces HCC cell proliferation and alters signaling independently of EMT.
Why the study?
The molecular mechanisms by which transglutaminase 2 contributes to hepatocellular carcinoma malignancy were unclear.
Does TG2 knockdown reduce cell proliferation and alter signaling pathways in hepatocellular carcinoma cells?
Population
Hepatocellular carcinoma cell lines
Comparison
TG2-knockdown (shTG2) vs control (shCtl) cell lines
Design
Preclinical comparative analysis using gene expression profiling
Authors
Loading...
TG2 knockdown may curb HCC proliferation via PI3K-Akt independently of EMT; leaves open whether targeting TG2 improves outcomes.
Does TG2 knockdown reduce cell proliferation and alter signaling pathways in hepatocellular carcinoma cells?
p-value: p=<0.0001
TG2 contributes to hepatocellular carcinoma malignancy by stimulating cell proliferation signaling pathways independently of epithelial-mesenchymal transition.
Yamaguchi et al. (2025) studied Hepatocellular carcinoma (n=366). Transglutaminase 2 (TG2) knockdown vs. Control (shCtl) cells was evaluated on Cell proliferation (p=<0.0001). Transglutaminase 2 knockdown significantly reduced cell proliferation in hepatocellular carcinoma cells and modulated signaling pathways independently of epithelial-mesenchymal transition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: